Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences
1. SMMT's ivonescimab shows improved overall survival trends in lung cancer patients. 2. Despite improvements, statistical significance was not achieved compared to p-value requirements. 3. Stock is down 18.17% due to mixed trial results and investor concerns. 4. Overall response rates with ivonescimab are higher than those with placebo. 5. Favorable safety profile noted, no new safety signals identified.